Treating chronic inflammatory diseases with JAK inhibitors
Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...
The Manila Times21h
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of ...
Medscape8d
New Bifunctional Drug Shows Sustained Effect in Alopecia Areata
In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...
Managed Healthcare Executive11d
Medicaid Coverage of JAK Inhibitors for Alopecia is Limited | AAD 2025
Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...
Yahoo Finance16d
Janus Kinase (JAK) Inhibitor Pipeline Market Insights Report 2025: Comprehensive Review of 50+ Companies and Respective 55+ Drugs
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. The "Janus Kinase (JAK ...
Nature7y
Where lies the blame for resistance—tumor or host?
A logical first approach might be to target appropriate members of the Janus kinase (JAK) family or the signal transducers and activators of transcription (STAT) family, as these proteins are ...
News Medical on MSN3d
JAK Inhibitors Target Chronic Inflammatory Diseases
Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis ...